Brainomix, Bridge Biotherapeutics partner

By staff writers

September 7, 2022 -- U.K. artificial intelligence (AI) software developer Brainomix and Bridge Biotherapeutics have partnered to deliver imaging biomarker analysis in a study that is testing Bridge's autotaxin inhibitor BBT-877 as a treatment for idiopathic pulmonary fibrosis (IPF).

Under the terms of the partnership, Brainomix will leverage its AI software, e-ILD technology, which has been trained to process high-resolution chest CT data in patients with interstitial lung diseases, including IPF and other conditions that cause progressive pulmonary fibrosis.

Using proprietary and patented objective imaging biomarkers and tracking changes over time, Brainomix will provide Bridge with insights and additional data on the efficacy and mechanism of action of BBT-877.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking